244 related articles for article (PubMed ID: 21131319)
21. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis.
Al-Abdely HM; Graybill JR; Bocanegra R; Najvar L; Montalbo E; Regen SL; Melby PC
Antimicrob Agents Chemother; 1998 Oct; 42(10):2542-8. PubMed ID: 9756753
[TBL] [Abstract][Full Text] [Related]
22. Genetic background influences immune responses and disease outcome of cutaneous L. mexicana infection in mice.
Rosas LE; Keiser T; Barbi J; Satoskar AA; Septer A; Kaczmarek J; Lezama-Davila CM; Satoskar AR
Int Immunol; 2005 Oct; 17(10):1347-57. PubMed ID: 16141242
[TBL] [Abstract][Full Text] [Related]
23. T-cell responses to immunodominant LACK antigen do not play a critical role in determining susceptibility of BALB/c mice to Leishmania mexicana.
Torrentera FA; Glaichenhaus N; Laman JD; Carlier Y
Infect Immun; 2001 Jan; 69(1):617-21. PubMed ID: 11119565
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
Nahrevanian H; Farahmand M; Aghighi Z; Assmar M; Amirkhani A
Exp Parasitol; 2007 Jul; 116(3):233-40. PubMed ID: 17335813
[TBL] [Abstract][Full Text] [Related]
25. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
26. In vivo and in vitro control of Leishmania mexicana due to garlic-induced NO production.
Gamboa-León MR; Aranda-González I; Mut-Martín M; García-Miss MR; Dumonteil E
Scand J Immunol; 2007 Nov; 66(5):508-14. PubMed ID: 17953527
[TBL] [Abstract][Full Text] [Related]
27. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.
Grogl M; Schuster BG; Ellis WY; Berman JD
J Parasitol; 1999 Apr; 85(2):354-9. PubMed ID: 10219319
[TBL] [Abstract][Full Text] [Related]
28. Leishmania spp: temperature sensitivity of promastigotes in vitro as a model for tropism in vivo.
Callahan HL; Portal IF; Bensinger SJ; Grogl M
Exp Parasitol; 1996 Dec; 84(3):400-9. PubMed ID: 8948329
[TBL] [Abstract][Full Text] [Related]
29. In vivo selection for Leishmania donovani miniexon genes that increase virulence in Leishmania major.
Zhang WW; Matlashewski G
Mol Microbiol; 2004 Nov; 54(4):1051-62. PubMed ID: 15522086
[TBL] [Abstract][Full Text] [Related]
30. S-nitrosoglutathione (GSNO) is cytotoxic to intracellular amastigotes and promotes healing of topically treated Leishmania major or Leishmania braziliensis skin lesions.
Costa IS; de Souza GF; de Oliveira MG; Abrahamsohn Ide A
J Antimicrob Chemother; 2013 Nov; 68(11):2561-8. PubMed ID: 23788476
[TBL] [Abstract][Full Text] [Related]
31. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
[TBL] [Abstract][Full Text] [Related]
32. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis.
Kückelhaus CS; Kückelhaus SA; Muniz-Junqueira MI
Exp Parasitol; 2011 Mar; 127(3):658-64. PubMed ID: 21176775
[TBL] [Abstract][Full Text] [Related]
33. Leishmania major: in vitro and in vivo anti-leishmanial effect of cantharidin.
Ghaffarifar F
Exp Parasitol; 2010 Oct; 126(2):126-9. PubMed ID: 20435039
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.
Maes L; Vanden Berghe D; Germonprez N; Quirijnen L; Cos P; De Kimpe N; Van Puyvelde L
Antimicrob Agents Chemother; 2004 Jan; 48(1):130-6. PubMed ID: 14693530
[TBL] [Abstract][Full Text] [Related]
35. Liposomal-lupane system as alternative chemotherapy against cutaneous leishmaniasis: macrophage as target cell.
Barros NB; Migliaccio V; Facundo VA; Ciancaglini P; Stábeli RG; Nicolete R; Silva-Jardim I
Exp Parasitol; 2013 Oct; 135(2):337-43. PubMed ID: 23933281
[TBL] [Abstract][Full Text] [Related]
36. A spectrum in the susceptibility of leishmanial strains to intracellular killing by murine macrophages.
Scott P; Sher A
J Immunol; 1986 Feb; 136(4):1461-6. PubMed ID: 3511147
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of anti-leishmanial activity by induction of nitric oxide and inhibition of prostaglandin in Balb/c mice infected with Leishmania major.
Nahrevanian H; Hajihosseini R; Arjmand M; Farahmand M; Ghasemi F
Southeast Asian J Trop Med Public Health; 2009 Nov; 40(6):1188-98. PubMed ID: 20578452
[TBL] [Abstract][Full Text] [Related]
38. Leishmania inactivation in human pheresis platelets by a psoralen (amotosalen HCl) and long-wavelength ultraviolet irradiation.
Eastman RT; Barrett LK; Dupuis K; Buckner FS; Van Voorhis WC
Transfusion; 2005 Sep; 45(9):1459-63. PubMed ID: 16131378
[TBL] [Abstract][Full Text] [Related]
39. SQ109 inhibits proliferation of Leishmania donovani by disruption of intracellular Ca
Gil Z; Martinez-Sotillo N; Pinto-Martinez A; Mejias F; Martinez JC; Galindo I; Oldfield E; Benaim G
Parasitol Res; 2020 Feb; 119(2):649-657. PubMed ID: 31897791
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis.
Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L
J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
